Placebo News and Research

RSS

Ardelyx announces positive Phase 2b results for tenapanor in IBS-C patients

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced positive results from its 371 patient Phase 2b clinical trial evaluating tenapanor in patients with constipation-predominant irritable bowel syndrome (IBS-C).

1 Oct 2014

Laser, needle acupuncture do not benefit patients with moderate to severe chronic knee pain

Among patients older than 50 years with moderate to severe chronic knee pain, neither laser nor needle acupuncture provided greater benefit on pain or function compared to sham laser acupuncture, according to a study in the October 1 issue of JAMA.

1 Oct 2014

Sanofi, Regeneron report positive Phase 2 study of dupilumab in patients with CSwNP

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that a Phase 2a proof-of-concept study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps (CSwNP) who did not respond to intranasal corticosteroids.

30 Sep 2014

Mymetics' innovative HIV vaccine candidate to enter new preclinical trial

Mymetics Corporation, a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate will enter a new preclinical trial to confirm excellent results obtained in a previous trial.

30 Sep 2014

Early exposure to marijuana can lead to immune-related diseases in adulthood

When it comes to using marijuana, new research, involving mice and published in the October 2014 issue of the Journal of Leukocyte Biology, suggests that just because you can do it, doesn't mean that you should. That's because a team of Italian scientists have found that using marijuana in adolescence may do serious long-term damage to the immune system.

30 Sep 2014

Combination treatment prevents disease progression in patients with advanced melanoma

New data announced today has demonstrated that combinational treatment of cobimetinib with Zelboraf (vemurafenib), the first personalised medicine to extend life in the first-line setting for over 30 years, in patients with advanced melanoma (BRAFV600 mutation-positive) can prevent disease progression (progression-free survival; PFS) by 9.9 months compared to 6.2 months following treatment of vemurafenib alone.

30 Sep 2014

AZD9291 shows median progression-free survival in patients with EGFRm T790M+ advanced NSCLC

Updated data from the ongoing AURA study of AZD9291 shows encouraging, although still immature, median progression free survival of 9.6 months (95% CI 8.3 to NC) in patients with epidermal growth factor receptor mutation positive (EGFRm) T790M+ advanced non-small cell lung cancer (NSCLC) who had disease progression following treatment with an EGFR tyrosine kinase inhibitor (EGFR TKI).

30 Sep 2014

Findings may shed light on risk factors associated with problem drinking among men

Consuming an alcoholic beverage may make men more responsive to the smiles of others in their social group, according to new research in Clinical Psychological Science, a journal of the Association for Psychological Science. The findings suggest that, for men, alcohol increases sensitivity to rewarding social behaviors like smiling, and may shed light on risk factors that contribute to problem drinking among men.

30 Sep 2014

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).

30 Sep 2014

Bausch + Lomb’s sub-micron loteprednol etabonate ophthalmic gel meets primary endpoint

Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), today announced that its next generation sub-micron gel formulation of loteprednol etabonate was statistically superior to placebo (vehicle gel) in eliminating inflammation and pain following cataract surgery by study day eight, the primary endpoints in the first Phase 3, multi-center, double-masked, vehicle-controlled, parallel-group study.

30 Sep 2014

Pertuzumab combined with trastuzumab and chemotherapy extends lives of HER2-positive breast cancer patients

Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone, updated results from the CLEOPATRA study reveal.

30 Sep 2014

Combination therapy achieves greater progression-free survival, response rates in melanoma

Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

30 Sep 2014

Targeted combination drug therapy can extend life, halt disease in metastatic melanoma patients

A world-first study in today's New England Journal of Medicine heralds the efficacy of a targeted combination drug therapy after reporting major declines in the risk of disease progression and death in people with metastatic melanoma.

29 Sep 2014

Curemark Founder to get Northstar Award for breakthrough autism research

Curemark, a leading drug research and development company focused on the treatment of neurological and other diseases, is proud to announce that Dr. Joan Fallon, Founder and CEO, will receive Springboard Enterprises' Northstar Award, as recognition for her entrepreneurial leadership and achievements in autism research.

29 Sep 2014

Cediranib combined with chemotherapy improves survival in recurrent cervical cancer

For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival, researchers report at the ESMO 2014 Congress in Madrid.

29 Sep 2014

Placebo News and Research

Ardelyx announces positive Phase 2b results for tenapanor in IBS-C patients

Laser, needle acupuncture do not benefit patients with moderate to severe chronic knee pain

Sanofi, Regeneron report positive Phase 2 study of dupilumab in patients with CSwNP

Mymetics' innovative HIV vaccine candidate to enter new preclinical trial

Early exposure to marijuana can lead to immune-related diseases in adulthood

Combination treatment prevents disease progression in patients with advanced melanoma

AZD9291 shows median progression-free survival in patients with EGFRm T790M+ advanced NSCLC

Findings may shed light on risk factors associated with problem drinking among men

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

Bausch + Lomb’s sub-micron loteprednol etabonate ophthalmic gel meets primary endpoint

Pertuzumab combined with trastuzumab and chemotherapy extends lives of HER2-positive breast cancer patients

Combination therapy achieves greater progression-free survival, response rates in melanoma

Targeted combination drug therapy can extend life, halt disease in metastatic melanoma patients

Curemark Founder to get Northstar Award for breakthrough autism research

Cediranib combined with chemotherapy improves survival in recurrent cervical cancer

NIH-funded clinical trial aims to restore vision in people who have lost vision due to IIH

Anamorelin drug safe and well tolerated in advanced non-small cell lung cancer, Phase III trial reveals

Phase III trial: Rolapitant lessens chemotherapy-induced nausea and vomiting

EMD Serono declares winners of first Grant for Oncology Innovation

MicroBiome Therapeutics' NM 505 drug can improve tolerability of metformin

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News